Skip to content
Dosage GuideResearch Reference

Modified GRF 1-29 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Modified GRF 1-29. All information is for educational purposes only.

Quick Answer

Modified GRF 1-29 is typically administered at 50-200 mcg per dose, 1-3 times daily via subcutaneous injection. It is frequently combined with a GHRP such as Ipamorelin or GHRP-2 for synergistic effects. The short half-life necessitates frequent dosing.

→ Modified GRF 1-29 Benefits→ Modified GRF 1-29 Side Effects→ Full Modified GRF 1-29 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 50–200 mcg per dose

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Growth Hormone Pulse Stimulation

100 mcg1–3× daily
Duration

8–12 weeks

Subcutaneous injection. Most commonly combined with a GHRP (e.g., Ipamorelin, GHRP-2). Cycle duration is typically 8-12 weeks followed by a 4-week break.

Improved Sleep Quality

100 mcg1× daily
Duration

4–8 weeks

Subcutaneous injection prior to sleep. Combined with Ipamorelin may further enhance sleep benefits. Monitor for potential side effects (see below).

Enhanced Muscle Recovery

100–200 mcg2–3× daily
Duration

6–12 weeks

Subcutaneous injection. Dosing around workout times may be beneficial. Ensure adequate protein intake and resistance training for optimal results.

Body Composition Improvement

100–200 mcg2× daily
Duration

8–12 weeks

Subcutaneous injection. Consistent diet and exercise are critical. Monitor blood glucose and lipid profiles during prolonged use.

Timing & Frequency

Administer subcutaneously at any time of day. For sleep enhancement, inject prior to bed. For muscle recovery, consider dosing around workout times. Given the short half-life, multiple daily injections may be required to maintain elevated GH levels, when combined with a GHRP.

Cycle Guidance

Typical cycles range from 6–12 weeks, followed by a break of 4–6 weeks. Cycling rationale is primarily precautionary given limited long-term human safety data. Monitor for any adverse effects and adjust dosage or discontinue use if necessary. Combining with other peptides (e.g., GHRPs) requires careful consideration of potential synergistic side effects.

Reconstitution Reference

Quick reference for reconstituting Modified GRF 1-29. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 2 mg per vial
BAC Water Volume1 mL bacteriostatic water for 2 mg/mL concentration
Concentration & DrawAt 2 mg/mL: 100 mcg = 0.05 mL (5 units on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 30 days refrigerated. Lyophilized powder stable 12–24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical Modified GRF 1-29 dosage?
The standard dosage is 50-200 mcg, administered 1-3 times daily via subcutaneous injection. It is almost always used with a GHRP for synergistic effects.
How long should I cycle Modified GRF 1-29?
Cycles typically last 6-12 weeks, followed by a 4-6 week break. This is a precautionary measure due to a lack of long-term safety data.
Can I combine Modified GRF 1-29 with other peptides?
Yes, it is commonly combined with GHRPs like Ipamorelin or GHRP-2 for synergistic growth hormone release. Be mindful of potential side effects when combining peptides.

Last updated: 2026-02-19